Piper Sandler has initiated coverage on ANI Pharmaceuticals (ANIP), a specialty pharmaceutical firm, with an ‘Overweight’ rating and a price target of $68. The firm highlights ANI’s successful transformation from a generics-focused company to a leader in rare disease therapies, driven by the success of its lead asset, Cortrophin Gel.
JP Morgan assesses the Specialty Pharmaceuticals sector, highlighting the resurgence of interest in new product launches. While the core fundamentals have strengthened, overall growth remains modest. The analyst offers insights into specific companies, providing ratings and outlining potential opportunities and concerns.
